Our Mission



The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.


Alfred Danielian, MD, FACC- Incoming Governor of Nevada speaks out on behalf of AED’s


ACC Rockies Chapter Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.


For more information and to register, please visit: ACC Rockies Chapter Meeting 2026



ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings


RSS feed: Latest in Cardiology from ACC.org Latest in Cardiology from ACC.org

  • Lp(a) HORIZON: Pelacarsen vs. Placebo in Patients With High Lp(a)
    Pelacarsen did not result in a lower risk of major adverse cardiovascular events compared with placebo in patients with preexisting cardiovascular disease and high lipoprotein(a) (Lp(a)) over a median follow-up period of approximately five years, based on findings from the Lp(a) HORIZON trial presented at AHA 2026 and simultaneously published in NEJM.
  • ZEUS: Interleukin-6 Inhibition With Ziltivekimab For High-Risk Patients With ASCVD, CKD and Systemic Inflammation
    Anti-inflammatory therapy targeting interleukin-6 (IL-1β) with ziltivekimab (a monoclonal antibody) did not lower risks of cardiovascular events compared with placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and systemic inflammation, based on findings from the ZEUS trial presented at AHA 2026 and simultaneously published in NEJM.
  • Kamala Tamirisa, MD, FACC, Named Next ACC BOG Chair-Elect
    The ACC has announced Kamala Tamirisa, MD, FACC, as the next chair-elect of the ACC Board of Governors (BOG). Tamirisa, who serves as the associate professor of internal medicine in the Division of Cardiology and director of electrophysiology research at UT Southwestern Medical Center in Dallas, TX, is currently governor of the ACC Texas Chapter […]
  • New Insights Across CV Medicine Take Center Stage in JACC Journals at AHA 2026
    Several studies from AHA 2026 exploring topics like precision screening for elevated lipoprotein(a), emerging cardio-oncology biomarkers, translational models for hypertrophic cardiomyopathy (HCM), and sex differences in heart failure (HF) are among the simultaneous publications included in JACC Journals.
  • 2027 Medicare Physician Fee Schedule Final Rule: An ACC Advocacy Deep Dive
    The 2027 Medicare Physician Fee Schedule (PFS) final rule released by the Centers for Medicare and Medicaid Services (CMS) on Nov. 3 includes a number of provisions important to cardiology. ACC Advocacy has developed the following overview addressing some of the most important highlights.